Figure 4From: DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer Low DEK level sensitizes to irinotecan and induces cleaved Caspase 3 expression. A) Ex vivo assay results for the tumor samples with the lowest (T1) and the highest (T2) DEK expression levels. SN38 treatment did not affect DEK expression, but a substantial reduction in Ki-67 and an increase in cleaved-Caspase 3 expression were observed in T1. No changes on Ki-67 or cleaved-Caspase 3 appeared in T2. B) Representative Western Blot of DEK, cleaved Caspase 3 and Actin expression after 72Ā hours of DEK downregulation in SW620 and DLD1 cells with siDEKsec57 (left panel). Densitometric data of Western Blot expressed as ratio of DEK/Actin and cleaved Caspase 3/Actin expression (right panel).Back to article page